{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:39:57Z","timestamp":1782477597255,"version":"3.54.5"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,8,1]],"date-time":"2027-08-01T00:00:00Z","timestamp":1817078400000},"content-version":"am","delay-in-days":608,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jpba.2025.117084","type":"journal-article","created":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T22:37:27Z","timestamp":1753569447000},"page":"117084","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Comprehensive assessments of pharmacokinetics and immunogenicity of farletuzumab ecteribulin, a novel antibody-drug conjugate against tumors expressing folate receptor \u03b1, in monkeys"],"prefix":"10.1016","volume":"266","author":[{"given":"Shawn","family":"Fernando","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8537-951X","authenticated-orcid":false,"given":"Yuji","family":"Mano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2025.117084_bib1","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1200\/JCO.2015.63.2596","article-title":"A randomized, double-blind, placebo-controlled, phase III study to assess efficacy and safety of weekly farletuzumab in combination with carboplatin and taxane in patients with ovarian cancer in first platinum-sensitive relapse","volume":"34","author":"Vergote","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jpba.2025.117084_bib2","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1158\/1535-7163.MCT-17-1215","article-title":"MORAb-202, an antibody-drug conjugate utilizing humanized anti-human FRalpha farletuzumab and the microtubule-targeting agent eribulin, has potent antitumor activity","volume":"17","author":"Cheng","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jpba.2025.117084_bib3","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1111\/cas.14898","article-title":"Antibody-drug conjugate MORAb-202 exhibits long-lasting antitumor efficacy in TNBC PDx models","volume":"112","author":"Furuuchi","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jpba.2025.117084_bib4","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1158\/1078-0432.CCR-20-4740","article-title":"First-in-human phase 1 study of MORAb-202, an antibody-drug conjugate comprising farletuzumab linked to eribulin mesylate, in patients with folate receptor-alpha-positive advanced solid tumors","volume":"27","author":"Shimizu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jpba.2025.117084_bib5","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Clinical Pharmacology Considerations for Antibody-Drug Conjugates, Guidance for Industry (2024). \u3008https:\/\/www.fda.gov\/media\/155997\/download\u3009. (accessed September 30)."},{"key":"10.1016\/j.jpba.2025.117084_bib6","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1002\/jssc.202200048","article-title":"A separate assay of released and liposomal encapsulated eribulin in dog plasma by liquid chromatography with tandem mass spectrometry for its application to a pharmacokinetic study","volume":"45","author":"Mano","year":"2022","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.jpba.2025.117084_bib7","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). Bioanalytical Method Validation, Guidance for Industry (2018). \u3008https:\/\/www.fda.gov\/media\/70858\/download\u3009. (accessed September 30)."},{"key":"10.1016\/j.jpba.2025.117084_bib8","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Immunogenicity Testing of Therapeutic Protein Products - Developing and Validating Assays for Anti-Drug Antibody Detection. Guidance for Industry (2019). https:\/\/www.fda.gov\/media\/119788\/download. (accessed September 30).."},{"key":"10.1016\/j.jpba.2025.117084_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2024.115993","article-title":"Generic UPLC-MS\/MS and Gyrolab assays with blood microsampling for pharmacokinetic assessments of therapeutic antibodies in mice","volume":"241","author":"Mano","year":"2024","journal-title":"J. Pharm. Biomed. Anal."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170852500425X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170852500425X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T02:07:46Z","timestamp":1762481266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073170852500425X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":9,"alternative-id":["S073170852500425X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2025.117084","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive assessments of pharmacokinetics and immunogenicity of farletuzumab ecteribulin, a novel antibody-drug conjugate against tumors expressing folate receptor \u03b1, in monkeys","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2025.117084","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117084"}}